The Global Thoracic Surgery Devices Market was valued at USD 750.8 million in 2024 and is estimated to grow at a CAGR of 6.3% to reach USD 1.37 billion by 2034. The market’s momentum is being fueled by the rising incidence of thoracic conditions such as chronic obstructive pulmonary disease (COPD), lung cancer, and other diseases requiring surgical intervention. A growing aging population, exposure to environmental pollutants, and persistent smoking habits are contributing to the increased prevalence of these conditions. This surge in cases is directly raising the demand for advanced thoracic surgical instruments that can deliver better outcomes. Minimally invasive procedures such as video-assisted and robot-assisted thoracic surgeries are gaining ground due to benefits like reduced recovery time, minimized postoperative discomfort, and lower risks of complications.
These advanced surgical approaches have not only improved patient recovery but also significantly reduced hospitalization time, enabling a broader range of procedures to be performed in outpatient environments. This shift has spurred the rapid growth of ambulatory surgical centers (ASCs), which are now seen as efficient, cost-effective, and patient-friendly alternatives to conventional inpatient hospital care. ASCs allow for quicker patient turnaround, lower overhead costs, and improved scheduling flexibility, making them an increasingly attractive option for both healthcare providers and patients. As minimally invasive techniques become more refined and equipment more compact and specialized, ASCs are expanding their capabilities to handle complex thoracic surgeries that were once only possible in high-acuity hospital settings, further accelerating market demand for advanced surgical devices tailored to these facilities.
In 2024, the staplers segment emerged as the top contributor, generating USD 205.9 million. Ongoing innovations in design, such as powered, digital, and articulating staplers, are enhancing precision, reducing complications like tissue leaks, and increasing surgical efficiency. These advanced features improve tissue handling and reduce operative time while assisting surgeons in managing complex thoracic anatomy with greater confidence and safety.
The lobectomy procedures segment held the largest share at 44.2% in 2024. This technique remains the preferred treatment for early-stage non-small cell lung cancer, which accounts for a significant majority of lung cancer diagnoses. As screening technologies and diagnostic methods improve, more patients, particularly older individuals and those with higher risk factors - are being identified earlier and becoming candidates for surgical treatment. This rise in operable cases is driving demand for specialized tools used in lobectomies, including vessel sealing instruments, dissection devices, and high-performance staplers.
United States Thoracic Surgery Devices Market was valued at USD 302.8 million in 2024. The country continues to see high rates of lung cancer and COPD, both of which frequently require surgical intervention during advanced stages. With millions affected by these conditions, healthcare providers in the U.S. are steadily performing thoracic surgeries in hospitals and cancer center settings. The consistent demand for surgical treatment ensures that the need for thoracic devices remains strong across healthcare institutions nationwide.
Key players shaping this market include GE Healthcare, Biolitec, Medela, Fujifilm Holdings, Olympus, MicroPort, Cook Medical, ConMed, B. Braun, Intuitive Surgical, Medtronic, Cardinal Health, Boston Scientific, Karl Storz, and Johnson & Johnson. To solidify their position in the thoracic surgery devices market, leading companies are focusing on innovation-driven strategies. These include launching next-generation surgical tools with enhanced ergonomics, precision, and real-time feedback. Many players are expanding their global footprint through strategic partnerships and regional distribution agreements. Others are investing in R&D to create devices compatible with minimally invasive and robotic-assisted procedures. Offering customized solutions for specific surgical applications and optimizing cost-effectiveness for outpatient settings are also top priorities. Additionally, companies are integrating digital technology into devices to improve surgical accuracy and postoperative outcomes, helping them attract a broader range of healthcare providers.
This product will be delivered within 2-4 business days.
These advanced surgical approaches have not only improved patient recovery but also significantly reduced hospitalization time, enabling a broader range of procedures to be performed in outpatient environments. This shift has spurred the rapid growth of ambulatory surgical centers (ASCs), which are now seen as efficient, cost-effective, and patient-friendly alternatives to conventional inpatient hospital care. ASCs allow for quicker patient turnaround, lower overhead costs, and improved scheduling flexibility, making them an increasingly attractive option for both healthcare providers and patients. As minimally invasive techniques become more refined and equipment more compact and specialized, ASCs are expanding their capabilities to handle complex thoracic surgeries that were once only possible in high-acuity hospital settings, further accelerating market demand for advanced surgical devices tailored to these facilities.
In 2024, the staplers segment emerged as the top contributor, generating USD 205.9 million. Ongoing innovations in design, such as powered, digital, and articulating staplers, are enhancing precision, reducing complications like tissue leaks, and increasing surgical efficiency. These advanced features improve tissue handling and reduce operative time while assisting surgeons in managing complex thoracic anatomy with greater confidence and safety.
The lobectomy procedures segment held the largest share at 44.2% in 2024. This technique remains the preferred treatment for early-stage non-small cell lung cancer, which accounts for a significant majority of lung cancer diagnoses. As screening technologies and diagnostic methods improve, more patients, particularly older individuals and those with higher risk factors - are being identified earlier and becoming candidates for surgical treatment. This rise in operable cases is driving demand for specialized tools used in lobectomies, including vessel sealing instruments, dissection devices, and high-performance staplers.
United States Thoracic Surgery Devices Market was valued at USD 302.8 million in 2024. The country continues to see high rates of lung cancer and COPD, both of which frequently require surgical intervention during advanced stages. With millions affected by these conditions, healthcare providers in the U.S. are steadily performing thoracic surgeries in hospitals and cancer center settings. The consistent demand for surgical treatment ensures that the need for thoracic devices remains strong across healthcare institutions nationwide.
Key players shaping this market include GE Healthcare, Biolitec, Medela, Fujifilm Holdings, Olympus, MicroPort, Cook Medical, ConMed, B. Braun, Intuitive Surgical, Medtronic, Cardinal Health, Boston Scientific, Karl Storz, and Johnson & Johnson. To solidify their position in the thoracic surgery devices market, leading companies are focusing on innovation-driven strategies. These include launching next-generation surgical tools with enhanced ergonomics, precision, and real-time feedback. Many players are expanding their global footprint through strategic partnerships and regional distribution agreements. Others are investing in R&D to create devices compatible with minimally invasive and robotic-assisted procedures. Offering customized solutions for specific surgical applications and optimizing cost-effectiveness for outpatient settings are also top priorities. Additionally, companies are integrating digital technology into devices to improve surgical accuracy and postoperative outcomes, helping them attract a broader range of healthcare providers.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, By Surgery Type, 2021 - 2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
Chapter 9 Company Profile
Companies Mentioned
- B. Braun
- Biolitec
- Boston Scientific
- Cardinal Health
- ConMed
- Cook Medical
- Fujifilm Holdings
- GE Healthcare
- Intuitive Surgical
- Johnson & Johnson
- Karl Storz
- Medela
- Medtronic
- MicroPort
- Olympus
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | July 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 750.8 Million |
| Forecasted Market Value ( USD | $ 1370 Million |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
